Evaluation of inhibitory effects of benzothiazole and 3-amino-benzothiazolium derivatives on DNA topoisomerase II by molecular modeling studies

Date
2014
Advisor
Supervisor
Co-Advisor
Co-Supervisor
Instructor
Source Title
SAR and QSAR in Environmental Research
Print ISSN
1062-936X
Electronic ISSN
1029-046X
Publisher
Taylor and Francis
Volume
25
Issue
8
Pages
637 - 649
Language
English
Type
Article
Journal Title
Journal ISSN
Volume Title
Series
Abstract

There has been considerable interest in DNA topoisomerases over the last decade, as they have been shown to be one of the major cellular targets in anticancer drug development. Previously we synthesized some benzothiazole derivatives and corresponding benzothiazolium forms, and tested their DNA inhibitory activity to develop novel antitumor agents. Among the 12 prepared compounds, compound BM3 (3-aminobenzothiazole-3-ium 4-methylbenzene sulfonate) exhibited extreme topoisomerase II inhibitory activity compared with the reference drug etoposide. We also tried to determine the DNA and enzyme binding abilities of BM3 and found that BM3 acted on topoisomerase II first at low doses, while it had also showed DNA minor groove binding properties at higher doses. In this study the interactions between DNA topoisomerase II and the compounds were examined in detail by molecular modelling studies such as molecular docking and pharmacophore analysis performed using Discovery Studio 3.5. As a result, it was found that benzothiazolium compounds exhibited a totally different mechanism than benzothiazoles by binding to the different amino acids at the active site of the protein molecule. 3-Aminobenzothiazoliums are worthy of carrying onto anticancer studies; BM3 especially would be a good anticancer candidate for preclinical studies.

Course
Other identifiers
Book Title
Keywords
Anticancer, Benzothiazole, Benzothiazolium, Molecular docking, Pharmacophore analysis, Topoisomerase II
Citation
Published Version (Please cite this version)